205 related articles for article (PubMed ID: 33219619)
1. Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population.
Ogiwara K; Swystun LL; Paine AS; Kepa S; Choi SJ; Rejtö J; Hopman W; Pabinger I; Lillicrap D
J Thromb Haemost; 2021 Mar; 19(3):654-663. PubMed ID: 33219619
[TBL] [Abstract][Full Text] [Related]
2. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
Swystun LL; Ogiwara K; Rawley O; Brown C; Georgescu I; Hopman W; Labarque V; Male C; Thom K; Blanchette VS; Carcao MD; Lillicrap D
Blood; 2019 Sep; 134(11):880-891. PubMed ID: 31350267
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
Elsheikh E; Lavin M; Heck LA; Larkin N; Mullaney B; Doherty D; Kennedy M; Keenan C; Guest T; O'Mahony B; Fazavana J; Fallon PG; Preston RJS; Gormley J; Ryan K; O'Connell NM; Singleton E; Byrne M; McGowan M; Roche S; Doyle M; Crowley MP; O'Shea SI; Reipert BM; Johnsen JM; Pipe SW; Di Paola J; Turecek PL; O'Donnell JS;
J Thromb Haemost; 2023 May; 21(5):1123-1134. PubMed ID: 36775768
[TBL] [Abstract][Full Text] [Related]
4. von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients.
van Moort I; Bukkems LH; Heijdra JM; Schutgens REG; Laros-van Gorkom BAP; Nieuwenhuizen L; van der Meer FJM; Fijnvandraat K; Ypma P; de Maat MPM; Leebeek FWG; Meijer K; Eikenboom J; Mathôt RAA; Cnossen MH;
Thromb Haemost; 2020 Jul; 120(7):1056-1065. PubMed ID: 32480417
[TBL] [Abstract][Full Text] [Related]
5. Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors.
Lunghi B; Morfini M; Martinelli N; Branchini A; Linari S; Castaman G; Bernardi F
Haemophilia; 2023 Mar; 29(2):479-487. PubMed ID: 36533781
[TBL] [Abstract][Full Text] [Related]
6. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study.
Pagliari MT; Rosendaal FR; Ahmadinejad M; Badiee Z; Baghaipour MR; Baronciani L; Benítez Hidalgo O; Bodó I; Budde U; Castaman G; Eshghi P; Goudemand J; Karimi M; Keikhaei B; Lassila R; Leebeek FWG; Lopez Fernandez MF; Mannucci PM; Marino R; Oldenburg J; Peake I; Santoro C; Schneppenheim R; Tiede A; Toogeh G; Tosetto A; Trossaert M; Yadegari H; Zetterberg EMK; Peyvandi F; Federici AB; Eikenboom J
J Thromb Haemost; 2022 May; 20(5):1106-1114. PubMed ID: 35092343
[TBL] [Abstract][Full Text] [Related]
7. The contribution of the sinusoidal endothelial cell receptors CLEC4M, stabilin-2, and SCARA5 to VWF-FVIII clearance in thrombosis and hemostasis.
Swystun LL; Michels A; Lillicrap D
J Thromb Haemost; 2023 Aug; 21(8):2007-2019. PubMed ID: 37085036
[TBL] [Abstract][Full Text] [Related]
8. Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients.
Garcia-Martínez I; Borràs N; Martorell M; Parra R; Altisent C; Ramírez L; Álvarez-Román MT; Nuñez R; Megias-Vericat JE; Corrales I; Alonso S; Vidal F
Thromb Haemost; 2020 Oct; 120(10):1395-1406. PubMed ID: 32726853
[TBL] [Abstract][Full Text] [Related]
9. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms.
Albánez S; Ogiwara K; Michels A; Hopman W; Grabell J; James P; Lillicrap D
J Thromb Haemost; 2016 May; 14(5):953-63. PubMed ID: 26875505
[TBL] [Abstract][Full Text] [Related]
10. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.
Eikenboom J; Federici AB; Dirven RJ; Castaman G; Rodeghiero F; Budde U; Schneppenheim R; Batlle J; Canciani MT; Goudemand J; Peake I; Goodeve A;
Blood; 2013 Mar; 121(12):2336-9. PubMed ID: 23349392
[TBL] [Abstract][Full Text] [Related]
11. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis.
Nossent AY; VAN Marion V; VAN Tilburg NH; Rosendaal FR; Bertina RM; VAN Mourik JA; Eikenboom HC
J Thromb Haemost; 2006 Dec; 4(12):2556-62. PubMed ID: 17059421
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
Boylan B; Rice AS; De Staercke C; Eyster ME; Yaish HM; Knoll CM; Bean CJ; Miller CH;
J Thromb Haemost; 2015 Jun; 13(6):1036-42. PubMed ID: 25780857
[TBL] [Abstract][Full Text] [Related]
13. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
[TBL] [Abstract][Full Text] [Related]
14. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
15. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
Lalezari S; Martinowitz U; Windyga J; Enriquez MM; Delesen H; Schwartz L; Scharrer I
Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.
Ozel AB; McGee B; Siemieniak D; Jacobi PM; Haberichter SL; Brody LC; Mills JL; Molloy AM; Ginsburg D; Li JZ; Desch KC
J Thromb Haemost; 2016 Sep; 14(9):1888-98. PubMed ID: 27359253
[TBL] [Abstract][Full Text] [Related]
17. von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group.
Davies JA; Collins PW; Hathaway LS; Bowen DJ
J Thromb Haemost; 2008 Jan; 6(1):97-103. PubMed ID: 17949477
[TBL] [Abstract][Full Text] [Related]
18. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease.
Sanders YV; Groeneveld D; Meijer K; Fijnvandraat K; Cnossen MH; van der Bom JG; Coppens M; de Meris J; Laros-van Gorkom BA; Mauser-Bunschoten EP; Leebeek FW; Eikenboom J;
Blood; 2015 May; 125(19):3006-13. PubMed ID: 25673639
[TBL] [Abstract][Full Text] [Related]
19. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
20. Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A.
Rejtő J; Königsbrügge O; Grilz E; Hofer S; Mauracher LM; Gabler C; Schuster G; Feistritzer C; Sunder-Plaßmann R; Quehenberger P; Gebhart J; Ay C; Pabinger I
J Thromb Haemost; 2020 May; 18(5):1081-1086. PubMed ID: 32073230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
